Savene
Submitted by Anonymous (not verified) on 23 April 2026 - 14:18
Savene
Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 22, Status: Authorised
Submitted by Anonymous (not verified) on 23 April 2026 - 13:59
Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 22, Status: Authorised
EMA business hours over King's Day and Labour Day, 27 April and 1 May
Submitted by Anonymous (not verified) on 23 April 2026 - 12:00
EMA business hours over King's Day and Labour Day, 27 April and 1 May
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Submitted by Anonymous (not verified) on 23 April 2026 - 10:00
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Referentials Management Service (RMS)
Submitted by Anonymous (not verified) on 23 April 2026 - 8:55
Referentials Management Service (RMS)
Human medicines European public assessment report (EPAR): Movymia, teriparatide, Date of authorisation: 11/01/2017, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 22 April 2026 - 16:22
Human medicines European public assessment report (EPAR): Movymia, teriparatide, Date of authorisation: 11/01/2017, Revision: 13, Status: Authorised
Orphan designation: aganirsen Prevention of corneal graft rejection, 20/04/2026 Positive
Submitted by Anonymous (not verified) on 22 April 2026 - 15:53
Orphan designation: aganirsen Prevention of corneal graft rejection, 20/04/2026 Positive
Orphan designation: surovatamig Treatment of large B-cell lymphoma, 20/04/2026 Positive
Submitted by Anonymous (not verified) on 22 April 2026 - 15:51
Orphan designation: surovatamig Treatment of large B-cell lymphoma, 20/04/2026 Positive
Orphan designation: 3-(4-((7-Cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)amino)-1H-imidazo[4,5-b]pyridin-6-yl)oxy)pyridin-2-yl)-1,1-dimethylurea Treatment of myelofibrosis, 20/04/2026 Positive
Submitted by Anonymous (not verified) on 22 April 2026 - 15:48
Orphan designation: 3-(4-((7-Cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)amino)-1H-imidazo[4,5-b]pyridin-6-yl)oxy)pyridin-2-yl)-1,1-dimethylurea Treatment of myelofibrosis, 20/04/2026 Positive
Orphan designation: adeno-associated virus serotype SLB101 containing the human microdystrophin gene Treatment of Duchenne muscular dystrophy, 20/04/2026 Positive
Submitted by Anonymous (not verified) on 22 April 2026 - 15:47
Orphan designation: adeno-associated virus serotype SLB101 containing the human microdystrophin gene Treatment of Duchenne muscular dystrophy, 20/04/2026 Positive